A postmenopausalis hormonpótló kezelés hatása a változókorban jelentkezo vérzészavarra

Translated title of the contribution: The effect of postmenopausal hormone replacement therapy on endometrial bleeding

Zoltán Magyar, Z. Csapó, Z. Papp

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: The aim of this study was to determine the effect of postmenopausal hormone replacement therapy (exclusively oestrogen or sequential/continuous combined oestrogen-progestogen treatment) on endometrial bleeding, including the histological alteration of the endometrium. Patients: From January 2000 to December 2005, 5893 women were treated by the authors in the menopause unit of their department. They examined the frequency of menopausal bleeding in treated and control groups. In case of bleeding, dilatation and fractional curettage was always carried out and the tissues were histologically evaluated. Results: In menopausal patients who did not obtain hormone replacement therapy, bleeding occured twice as frequently as in the treated group. Proliferating or hyperplastic endometriurn was observed mainly among the treated patients, suggesting that in due time, even before the age of menopause, hormonal treatment might decrease hyperplasia and indirectly the chance of occurrence of adenocarcinoma. Hyperplasia was found more frequently in patients obtaining only oestrogen. According to the authors' view, unbalanced oestrogen treatment might further aggravate the existing hyperplasia of the endometrium. In the group treated with hormonal therapy, only simplex hyperplasia was observed. No case of complex hyperplasia with atypia was found among these patients. In the majority of patients on continuous balanced hormonal therapy, the myometrium underwent atrophy and the frequency of hyperplasia, including the chance of bleeding, mostly decreased. Endometrial polyps most frequently were found under hormonal therapy, but no acceptable explanation can be provided. The rate of cervical polyps was also higher in this group. Conclusions: According to the observations of the authors, hormone replacement therapy does not increase the risk of endometrial carcinoma. Combined preparations decrease the frequency of hyperplasia and consequently the chance of occurrence of adenocarcinoma.

Original languageHungarian
Pages (from-to)1451-1459
Number of pages9
JournalOrvosi Hetilap
Volume148
Issue number31
DOIs
Publication statusPublished - Aug 5 2007

Fingerprint

Estrogen Replacement Therapy
Hyperplasia
Hemorrhage
Estrogens
Hormone Replacement Therapy
Menopause
Endometrium
Polyps
Adenocarcinoma
Therapeutics
Dilatation and Curettage
Myometrium
Progestins
Endometrial Neoplasms
Atrophy
Control Groups

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A postmenopausalis hormonpótló kezelés hatása a változókorban jelentkezo vérzészavarra. / Magyar, Zoltán; Csapó, Z.; Papp, Z.

In: Orvosi Hetilap, Vol. 148, No. 31, 05.08.2007, p. 1451-1459.

Research output: Contribution to journalArticle

@article{d041f0d5d95a45849d3398a720c8f5e5,
title = "A postmenopausalis hormonp{\'o}tl{\'o} kezel{\'e}s hat{\'a}sa a v{\'a}ltoz{\'o}korban jelentkezo v{\'e}rz{\'e}szavarra",
abstract = "Objective: The aim of this study was to determine the effect of postmenopausal hormone replacement therapy (exclusively oestrogen or sequential/continuous combined oestrogen-progestogen treatment) on endometrial bleeding, including the histological alteration of the endometrium. Patients: From January 2000 to December 2005, 5893 women were treated by the authors in the menopause unit of their department. They examined the frequency of menopausal bleeding in treated and control groups. In case of bleeding, dilatation and fractional curettage was always carried out and the tissues were histologically evaluated. Results: In menopausal patients who did not obtain hormone replacement therapy, bleeding occured twice as frequently as in the treated group. Proliferating or hyperplastic endometriurn was observed mainly among the treated patients, suggesting that in due time, even before the age of menopause, hormonal treatment might decrease hyperplasia and indirectly the chance of occurrence of adenocarcinoma. Hyperplasia was found more frequently in patients obtaining only oestrogen. According to the authors' view, unbalanced oestrogen treatment might further aggravate the existing hyperplasia of the endometrium. In the group treated with hormonal therapy, only simplex hyperplasia was observed. No case of complex hyperplasia with atypia was found among these patients. In the majority of patients on continuous balanced hormonal therapy, the myometrium underwent atrophy and the frequency of hyperplasia, including the chance of bleeding, mostly decreased. Endometrial polyps most frequently were found under hormonal therapy, but no acceptable explanation can be provided. The rate of cervical polyps was also higher in this group. Conclusions: According to the observations of the authors, hormone replacement therapy does not increase the risk of endometrial carcinoma. Combined preparations decrease the frequency of hyperplasia and consequently the chance of occurrence of adenocarcinoma.",
keywords = "Bleeding disturbances, Climacterium, Menopause, Postmenopausal hormone therapy",
author = "Zolt{\'a}n Magyar and Z. Csap{\'o} and Z. Papp",
year = "2007",
month = "8",
day = "5",
doi = "10.1556/OH.2007.28000",
language = "Hungarian",
volume = "148",
pages = "1451--1459",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "31",

}

TY - JOUR

T1 - A postmenopausalis hormonpótló kezelés hatása a változókorban jelentkezo vérzészavarra

AU - Magyar, Zoltán

AU - Csapó, Z.

AU - Papp, Z.

PY - 2007/8/5

Y1 - 2007/8/5

N2 - Objective: The aim of this study was to determine the effect of postmenopausal hormone replacement therapy (exclusively oestrogen or sequential/continuous combined oestrogen-progestogen treatment) on endometrial bleeding, including the histological alteration of the endometrium. Patients: From January 2000 to December 2005, 5893 women were treated by the authors in the menopause unit of their department. They examined the frequency of menopausal bleeding in treated and control groups. In case of bleeding, dilatation and fractional curettage was always carried out and the tissues were histologically evaluated. Results: In menopausal patients who did not obtain hormone replacement therapy, bleeding occured twice as frequently as in the treated group. Proliferating or hyperplastic endometriurn was observed mainly among the treated patients, suggesting that in due time, even before the age of menopause, hormonal treatment might decrease hyperplasia and indirectly the chance of occurrence of adenocarcinoma. Hyperplasia was found more frequently in patients obtaining only oestrogen. According to the authors' view, unbalanced oestrogen treatment might further aggravate the existing hyperplasia of the endometrium. In the group treated with hormonal therapy, only simplex hyperplasia was observed. No case of complex hyperplasia with atypia was found among these patients. In the majority of patients on continuous balanced hormonal therapy, the myometrium underwent atrophy and the frequency of hyperplasia, including the chance of bleeding, mostly decreased. Endometrial polyps most frequently were found under hormonal therapy, but no acceptable explanation can be provided. The rate of cervical polyps was also higher in this group. Conclusions: According to the observations of the authors, hormone replacement therapy does not increase the risk of endometrial carcinoma. Combined preparations decrease the frequency of hyperplasia and consequently the chance of occurrence of adenocarcinoma.

AB - Objective: The aim of this study was to determine the effect of postmenopausal hormone replacement therapy (exclusively oestrogen or sequential/continuous combined oestrogen-progestogen treatment) on endometrial bleeding, including the histological alteration of the endometrium. Patients: From January 2000 to December 2005, 5893 women were treated by the authors in the menopause unit of their department. They examined the frequency of menopausal bleeding in treated and control groups. In case of bleeding, dilatation and fractional curettage was always carried out and the tissues were histologically evaluated. Results: In menopausal patients who did not obtain hormone replacement therapy, bleeding occured twice as frequently as in the treated group. Proliferating or hyperplastic endometriurn was observed mainly among the treated patients, suggesting that in due time, even before the age of menopause, hormonal treatment might decrease hyperplasia and indirectly the chance of occurrence of adenocarcinoma. Hyperplasia was found more frequently in patients obtaining only oestrogen. According to the authors' view, unbalanced oestrogen treatment might further aggravate the existing hyperplasia of the endometrium. In the group treated with hormonal therapy, only simplex hyperplasia was observed. No case of complex hyperplasia with atypia was found among these patients. In the majority of patients on continuous balanced hormonal therapy, the myometrium underwent atrophy and the frequency of hyperplasia, including the chance of bleeding, mostly decreased. Endometrial polyps most frequently were found under hormonal therapy, but no acceptable explanation can be provided. The rate of cervical polyps was also higher in this group. Conclusions: According to the observations of the authors, hormone replacement therapy does not increase the risk of endometrial carcinoma. Combined preparations decrease the frequency of hyperplasia and consequently the chance of occurrence of adenocarcinoma.

KW - Bleeding disturbances

KW - Climacterium

KW - Menopause

KW - Postmenopausal hormone therapy

UR - http://www.scopus.com/inward/record.url?scp=34848895472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848895472&partnerID=8YFLogxK

U2 - 10.1556/OH.2007.28000

DO - 10.1556/OH.2007.28000

M3 - Article

C2 - 17656335

AN - SCOPUS:34848895472

VL - 148

SP - 1451

EP - 1459

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 31

ER -